| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_55ad301cc7a70e081404f170702e471a |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2833
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2846
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P39-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2072
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2027
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-204
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2009
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2018
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4422
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4412
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-284 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4412
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-28 |
| filingDate |
2018-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_421c6f0bc1078a50bb5e018356a8fd41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2e3f742ef1abc5ba0c3e3aa2016604a9 |
| publicationDate |
2019-04-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2019117581-A1 |
| titleOfInvention |
Delayed release deferiprone tablets and methods of using the same |
| abstract |
The invention is directed to pharmaceutical compositions such as tablets that exhibit delayed release properties when administered as either whole or half tablets. The invention is also directed to delayed release tablets comprising deferiprone for oral administration, for which twice daily administration is bioequivalent to the same daily dose of an immediate release tablet administered thrice daily. The invention is also directed to methods of making and using the same. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11607389-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10780055-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11723874-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11357731-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10940115-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11458103-B2 |
| priorityDate |
2017-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |